Patient-reported outcomes in patients with hematological relapse or progressive disease: a longitudinal observational study

Table 2 Clinical and sociodemographic characteristics of the included patients with hematological relapse

Characteristics	Total (%) N = 90 (100)
Sex
Female	30 (33.3)
Male	60 (66.7)
Median age, years	69.5 (range, 34–93)
Age
Age < 70	45 (50)
Age ≥ 70	45 (50)
Diagnosis
Acute leukemia^¥	9 (10)
Aggressive lymphoma^¶	26 (28.9)
Chronic leukemia^ǂ	18 (20)
Indolent lymphoma^§	22 (24.4)
Multiple myeloma	15 (16.7)
Treatment intent
Curative	19 (21.1)
Non-curative	71 (78.9)
Expected survival
≤ 2 years	25 (27.8)
> 2 years	65 (72.2)
Charlson’s Comorbidity Index
0–2	33 (36.7)
3–4	40 (44.4)
5+	17 (18.9)
Number of relapse/progressions*
1	57 (63.3)
2	18 (20)
3+	15 (16.7)
Marital status
Co-habiting	72 (80)
Single	18 (20)
Employment status
Employed	19 (21.1)
Unemployed/retired	68 (75.6)
N/A	3 (3.3)
Mode of completion
Electronic	70 (77.8)
Paper	20 (22.2)

^¶Aggressive lymphomas included: diffuse large B-cell lymphoma, Hodgkin lymphoma, non-Hodgkin lymphoma, T-cell large granular lymphocytic leukemia, angioimmunoblastic T-cell lymphoma
^ǂChronic leukemias included: chronic lymphocytic leukemia, small lymphocytic leukemia, chronic myeloid leukemia, hairy cell leukemia
^§Indolent lymphomas included: follicular lymphoma, maltoma, mantle cell lymphoma, nodal marginal zone lymphoma, lymphoplasmacytic lymphoma, Waldenström’s macroglubulinemia, splenic marginal zone lymphoma, peripheral T-cell lymphoma
^¥Acute leukemias included: Acute myeloid leukemia, acute lymphoid leukemia, myelodysplastic syndrome
^*Including the current relapse/progression

ISSN: 1477-7525